



## The Role of Long Non-coding RNA in Cancer

Guest Editor:

### Dr. Dhiraj Kumar

Department of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA

Deadline for manuscript submissions:

**closed (31 August 2023)**

### Message from the Guest Editor

The role of lncRNAs is still unclear and currently under investigation in cancer progression, dormancy, and metastasis. lncRNAs are a class of transcripts with diverse and largely uncharacterized biological functions involved in various biological processes and have been proposed to be key players in diseases including cancers. Through crosstalk with chromatin, DNA, RNA species and proteins, lncRNAs play an important role in chromatin remodeling, as well as transcriptional and post-transcriptional regulation. The lncRNAs mediated genetic or epigenetic alterations in disseminated tumor cells regulate metastatic niches which play a significant role to define the fate of dormant tumor cells in reactivation. The rate-limiting step of the metastatic process can be influenced by various immune cells in a tumor microenvironment (TME). Despite all these findings, the role of tumor intrinsic lncRNAs in the regulation of metastatic reactivation and immune evasion remains unclear. Understanding the mechanisms of lncRNAs during cancer dormancy, metastasis and tumor immune microenvironment would be highly valuable to identify novel targets to combat cancer metastasis and relapse.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)